The latest issue of Vancouver Coastal Health Research Institute News includes a discussion with Dr. Ralph Buttyan on his Prostate Cancer Canada - Movember funded team research program. The article "How Movember’s moustaches are taking prostate cancer down" is available here.
This week, the Canadian Task Force on Preventive Health Care recommended not using PSA as a screening test for prostate cancer.
September 26, 2014 - Prostate Cancer Canada today annouced the results of their funding decision in their Translation Acceleration Grant competition TAG2: Novel Therapeutics for Advanced Disease. This funding is for groups studying novel therapeutics and treatment options for metastatic and castrate-resistant prostate cancer, for projects aimed at eliminating advanced disease from affected men.
SHENZHEN, China and VANCOUVER, British Columbia, September 12, 2014 – BGI, the world’s largest genomics organization, based in China, and The Vancouver Prostate Centre (VPC), a global leader in translational research in cancer, today announced the establishment of the BGI-VPC Joint Research Laboratory, a sequencing and translational research facility, to jointly discover and advance basic and translational programs in oncology, including precision oncology.
Sequencing RNA, not just DNA, could help doctors predict how prostate cancer tumors will respond to treatment, according to research published in the open access journalGenome Biology. Because a tumor’s RNA shows the real time changes a treatment is causing, the authors think this could be a useful tool to aid diagnosis and predict which treatment will most benefit individual cancer patients.
With the awarding of $14.5M under the Canadian government’s Networks of Centres of Excellence (Centres of Excellence for Commercialization and Research (CECR)) Program, as announced earlier this morning by the Honourable Ed Holder, Minister of State for Science and Technology, Accel-Rx - Canada’s Health Sciences Accelerator is officially launched.
A new blood test developed by researchers at the BC Cancer Agency and the Vancouver Prostate Centre is garnering international attention, and has the potential to improve the way a deadly form of prostate cancer, metastatic castration-resistant prostate cancer (CRPC), is treated.
The Coalition to Cure Prostate Cancer (CCPC) Special Challenge Award will fund the Prostate Cancer Extinction Research program under the leadership of Dr. Martin Gleave of the University of British Columbia and Vancouver Prostate Centre.